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the expense of radiation-induced late toxicity. Progressive 
cell depletion and inflammation are the leading mechanisms 
of acute toxicity which is observed during or shortly after 
treatment. The pathogenetic pathways of late toxicity, 
developing 90 days or later after the onset of radiotherapy, 
are more complex and involve processes such as vascular 
sclerosis and fibrosis. Since many patients have become long-
term survivors, awareness and recognition of radiation-
related toxicity has gained in importance and increased 
efforts are made for its prevention and management.  
Technical innovations contribute to a reduction in 
radiotherapy-associated toxicity. The steep dose gradients of 
highly-conformal radiotherapy techniques allow for an 
accurate dose delivery with optimal sparing of the normal 
tissues. Several studies have demonstrated the dosimetrical 
benefit of intensity-modulated radiotherapy (IMRT) and 
volumetric modulated arc radiotherapy (VMAT) compared to 
conventional radiotherapy techniques. It has been shown that 
the dosimetrical benefit of IMRT translated into a clinically 
significant reduction in lower gastrointestinal toxicity 
compared with three-field conventional radiotherapy. In the 
near future MRI-linacs and proton therapy are likely to 
broaden the therapeutic window further. Prone positioning 
on a bellyboard reduces small bowel toxicity by pushing away 
the small bowel loops from the high dose region. Image-
guided radiotherapy allows for an accurate definition, 
localization and monitoring of tumor position, size and shape 
before and during treatment and may help to reduce set-up 
margins.  
Small randomized controlled trials have shown that the 
administration of several agents might have a beneficial 
effect for the prevention of acute (e.g. intrarectal 
amifostine, oral sulfasalazine and balsalazide) and/or late-
onset radiation-induced toxicity (intrarectal beclomethasone 
and oral probiotics). Once severe toxicity develops, total 
replacement of the diet with elemental formula may be 
appropriate. Probiotics influence the bacterial microflora and 
seem promising in reducing the incidence and severity of 
radiation-induced diarrhea. Currently there is insufficient 
evidence for cytoprotective and anti-inflammatory drugs in 
the management of radiation-induced toxicity. Future 
challenges lie in the prediction of treatment-related toxicity, 
which might be a promising step towards an individualized 
risk-adapted treatment. 
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As the cure rates for childhood cancers continue to improve 
with better local control and outcome, the incidence and 
management of long-term consequences are a constant 
challenge. Conservative treatments include a combination of 
chemotherapy, radiotherapy and surgery that may lead to 5 
year-survival rates > 90%. The use of brachytherapy, 
whenever feasible, is an attractive alternative when ionizing 
radiation is needed for the treatment of paediatric cancers, 
especially rhabdomyosarcomas (RMS). In genital RMS, 
brachytherapy represents an alternative to radical surgery: 
hysterectomy or colpectomy in girls and cysto-prostatectomy 
in boys. When brachytherapy is properly applied, the 
probability of late complications remains low with a high 
cure-rate. At Gustave Roussy Hospital, since decades, 
brachytherapy –when possible– has been proposed as an 
alternative to external irradiation or radical surgery. So far, 
more than 150 children have been treated with 
brachytherapy, in the context of multidisciplinary approach, 
including chemotherapy +/- conservative surgery. The most 
frequent tumour sites were vagina/uterine cervix, 
bladder/prostate and nasolabial fold, the most common 
histopathological type being RMS. In a series of 39 girls 
treated between 1971 and 2005, interstitial brachytherapy 
was used for vulval tumors, and endocavitary brachytherapy 
was used in vaginal tumours with individually tailored 
moulded vaginal applicators. Among them, 20 patients were 
treated before 1990, where the initial tumoral extension was 
included in the brachytherapy volume, while after 1990, only 
residual disease after initial chemotherapy was treated. The 
usual prescribed dose was 60-65 Gy delivered in one to three 
brachytherapy applications, taking into account the doses to 
organs at risk. With a median follow of 8.4 years, local 
recurrence was reported in 2 patients (5.1%) in the first year 
following the treatment, regional relapse in 1 patient (2.6%) 
and distant recurrences in 7 patients (17.9%). Among the 20 
patients treated before 1990, 15 presented long-term 
sequelae, (vaginal or urethral sclerosis or stenosis) with three 
requiring surgical treatment. By contrast, among the 19 
patients treated after 1990, four patients had vaginal or 
urethral stenosis, none of them requiring surgery. A recent 
long-term toxicity analysis confirmed the increase of the 
total number of G3-4 late effects in patients treated before 
1990. From 1991 to 2007, 26 boys with bladder/prostate RMS 
were treated with brachytherapy as a perioperative 
procedure. All of them underwent a conservative surgical 
procedure, with bladder-neck and urethra preservation. 
Brachytherapy was systematically performed after tumor 
resection, consisting of two loops encompassing the prostate 
and the bladder-neck area. A total dose of 60 Gy was 
delivered with low dose rate. With a median follow-up of 4 
years (10 months-14.5 years), only one patient locally 
relapsed out of the brachytherapy treated area. Among 11 
boys older than 6 years, 9 (82%) were normally continent, 
two had diurnal dribbling treated by bladder education. 
Recently, sexual and urinary functions, assessed with a 
quality of life (QoL) questionnaire, were studied in a cohort 
of 22 long-term survivors. The results showed that the great 
majority of long terms surviving males (76%) considered 
themselves as having normal QoL. Between 1971 and 2005, 16 
children with RMS of the nasolabial fold were treated with 
brachytherapy. Ten presented embryonal RMS and six 
alveolar RMS. In 12 cases, brachytherapy was combined with 
local excision. The doses ranged from 50 to 70 Gy, depending 
on chemotherapy response, and surgical margins. With a 
median follow-up of 4.4 years (1.7–33), 10 patients relapsed: 
4 local, 6 regional, and 2 metastatic failures were reported. 
In this particular context, brachytherapy provided an 
acceptable local control rate, but with a poor regional 
control. The ballistic interest of BT has been clearly 
demonstrated in paediatric RMS, with a very high dose 
gradient, sparing normal tissue and very high tumor dose. In 
our experience low dose-rate brachytherapy was used and 
recently had to move to pulsed dose-rate brachytherapy. 
Such conservative approach, minimizing late sequelae 
without detrimental effect on local control, should be 
offered whenever possible. This treatment is a clear 
demonstration of the multidisciplinary team approach, 
including surgeons, pediatricians and radiation oncologists. 
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Radiotherapy has relied on computed tomography (CT) for 
both target definition and treatment planning during the last 
decades. However, the increasing accuracy in radiation 
delivery, through highly conformal techniques such as 
intensity modulated radiotherapy (IMRT) and image guided 
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radiotherapy (IGRT), has highlighted deficiencies in target 
delineations based on CT. Several studies have shown large 
variability in target definitions based on CT, for multiple 
treatment sites. To address this issue, magnetic resonance 
imaging (MRI) has made its way into the clinical routine at 
modern radiotherapy departments over the last years. This, 
however, has presented several new problems that need to 
be solved. 
The traditional method of including MR information in the 
radiotherapy process is as a complement to the CT. To 
accomplish this in an integrated and accurate fashion, the 
images must be placed in a common coordinate system 
through image registration. This process in itself introduces 
new uncertainties into the treatment chain, which must be 
quantified and minimized. Another method of using MR 
information is to base the entire treatment on MR and 
exclude the CT altogether. This alleviates uncertainties that 
stem from the image registration process, but introduces 
another set of problems. To perform accurate dose 
calculations, heterogeneity corrections based on CT data 
have been the clinical standard for many years. MR data does 
not provide information that can be used for such 
corrections; however, much research effort has been 
invested in creating valid photon attenuation maps from MR 
data over the last years.  
Whatever method employed, MR for radiotherapy purposes 
also imposes practical issues that need to be addressed. The 
patient needs to be positioned in the same way that will be 
employed during the radiotherapy itself. This includes a flat 
table top and immobilization devices such as cast masks and 
tilted boards, which may not be MR compatible. For example, 
many radiotherapy fixation devices can contain metal parts 
such as nuts and bolts, which cannot be used in the MR. 
Plastic replacements must be used instead. Also, the 
standard MR coils will often not accommodate the 
immobilized patient, which forces MR adopters to acquire 
special coils or coil holders for flexible coils to be able to 
scan the patient in the radiotherapy treatment position. 
MR images do not have the same geometric integrity as CT, 
which is an issue in the radiotherapy setting. The image 
distortions can come from the machine itself or from the 
patient that is in the machine. Machine specific distortions 
are caused by inhomogeneity in the main magnetic field or 
gradient non-linearity. Patient specific distortions are mostly 
caused by susceptibility effects. The machine specific 
distortions can be measured, modelled and corrected for to a 
certain extent, while patient specific distortions often needs 
to be handled by choosing imaging parameters wisely.  
In the end, the images acquired from the MR scanner must be 
of sufficient quality to allow physicians to base the 
radiotherapy treatment on them. MR for radiotherapy has a 
different set of demands on the images than their diagnostic 
counterparts, for example slice thickness and gap, as well as 
other parameters. Also, the vast variety of MR contrasts may 
be an initial obstacle for radiotherapy oncologists. Many 
studies have shown differences in target definitions based on 
CT and MR images, and the effects of these changes in target 
volumes have not yet been studied in clinical trials. 
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Interest in proton therapy continues to grow worldwide, yet 
access to proton therapy facilities remains relatively low 
compared to those offering conventional radiotherapy. As a 
consequence, pressure exists to maximize patient throughput 
in each facility. Most facilities operate 24 hours per day, 7 
days per week to meet the demands of the clinical load and 
to complete machine maintenance, routine quality 
assurance, and patient specific quality assurance. With the 
advent of advanced delivery techniques such as pencil beam 
scanning, the complexity of patient specific quality assurance 
is increasing. However, there is a need to improve efficiency 
of these tests whilst maintaining accuracy. 
This presentation will summarize contemporary patient 
specific quality assurance practice for both passive scattering 
and pencil beam scanning proton therapy, and describe off-
line tests that potentially enable improved efficiency. 
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Radiotherapy (RT) is an effective option for treatment of 
many cancers. It offers organ and functional preservation and 
enhances surgical outcomes when administered pre-
operatively or post-operatively, and for some diseases, such 
as nasopharyngeal cancer, it is often the only curative 
option. Disease control is generally of paramount importance 
to most patients during the urgent point of decision-making 
following diagnosis. However toxicity will almost certainly 
emerge as being just as relevant in the aftermath of 
treatment and in the subsequent follow-up period. In 
essence, when a patient dies of toxicity or treatment-related 
complications, it is just as tragic as dying of disease. The 
long-term result of RTOG 9111 and 9501 suggest that 
treatment -related deaths are blunting originally observed 
difference in cancer-related outcome. The recent RTOG 0617 
trial was designed to test whether a higher RT dose (74 Gy vs 
60 Gy) +/- cetuximab could confer a survival benefit but 
showed an unexpected therapeutic “disadvantage” with 
higher RT dose attributable to significant acute and late 
toxicities. These findings highlight the importance of 
balancing toxicity and disease control to optimize 
therapeutic gain. Several strategies have been employed to 
mitigate toxicities, such as respecting the biology of 
radiation injury by altered dose fractionation (typically using 
smaller than conventional fractions), or optimising 
radiotherapy technical delivery to reduce dose to vulnerable 
anatomy. Implementing novel RT technologies need to be 
closely monitored to prove clinical benefit. Historical lessons 
have shown that putative benefits may not always transfer to 
real clinical advantages since many unforeseen factors may 
modify potential anticipated gains. While modern RT 
technologies, such as IMRT-IGRT, adaptive, and IMPT provide 
opportunities to reduce RT late toxicity by providing more 
conformal dose distribution to spatially avoid normal tissue, 
the steps to achieve this are complex. One needs to 
appreciate many diverse factors. These include radiobiology 
of normal tissue (dose/constraints), optimal imaging quality 
and registration, systematic quality control involving “target” 
delineation to delivery, and knowledge of a variety of 
inherent pitfalls in the process(e.g. poor delineation, dose 
dumping, erratic planning, tumor or normal tissue 
deformation, and set up uncertainties that may emerge 
throughout the treatment course). For example, beam path 
toxicities have been reported due to “dose dumping” from 
parotid-sparing IMRT in head and neck cancer. Increased 
local failure has been observed when delivering tight margin 
carotid-sparing partial organ irradiation for T2 glottic cancer 
using vertebrae rather than laryngeal soft tissue as the image 
guidance surrogate. Adaptive radiotherapy appears to be 
feasible in some situations but the therapeutic advantages 
are yet to be proven and may be tedious and inefficient 
under the current technical configurations of many 
departments. Also, while intensity-modulated proton therapy 
(IMPT) is an attractive emerging approach that is probably 
able to spare normal tissue, indications and clinical benefit 
are also largely unproven at this time. The path to 
implementing these approaches will require rigorous 
